Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma

NCT05179603 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05179603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05179603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Non-randomized, Open-label, Multi-cohort, Multicenter Study Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Terminated
Start date
December 7, 2021
Completion date
September 6, 2024
Enrollment
14 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

classic hodgkin lymphoma, diffuse large b-cell lymphoma